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Abstract
Purpose Main aim was to estimate the association
between use of exogenous hormones and breast cancer
(BC) risk in a large population-based survey, and to assess
the representativeness and overall validity of the data.
Methods The survey ‘Women’s Health and Use of Hor-
mones’ was conducted in Finland in 2009, including 7,000
BC cases and 20,000 matched population controls. Con-
ditional logistic regression was used to estimate odds ratios
and their 95 % confidence interval. For validation, expo-
sure prevalences were compared with population data from
Statistics Finland and two large population-based surveys.
Results We found positive associations with BC risk and
exclusive use of hormone-releasing intrauterine device
(HR IUD) in postmenopausal women (1.48, 95 % CI
1.10–1.99), when compared to never-users of any hor-
monal contraceptive and considering only prediagnostic
use in cases. Regarding use of other hormonal contracep-
tives (HC), a positive association between long HC use
(C2 years) and BC was observed in both groups, OR being
1.37 (95 % CI 1.12–1.68) for premenopausal and 1.11
(95 % CI 1.03–1.20) for postmenopausal women, when
compared to never-users of other HC.
Conclusions Observed association between HR IUD use
and risk of BC in postmenopausal women is worrying and
deserves further attention. Selection bias seemed not to
explain this result. Considering the increasing popularity of
HR IUD use in, e.g., USA, impact of possible adverse
effects in public health could be significant.
Keywords Hormonal contraceptives  Intrauterine
device  Case–control study  Breast cancer  Epidemiology
Introduction
Breast cancer (BC) is the most common cancer among
Finnish women with approximately 4,500 new cases
annually [1] and an age-standardized incidence rate of c.
90/100,000. Incidence has increased steadily over the past
decade with approximately 1.3 % per year. This trend is
expected to continue, and the age-standardized rate is
predicted to reach 100/100,000 in year 2016 [2]. Currently,
the incidence of BC increases markedly after 45 years of
age and peaks at 60 years [2]. Nationwide organized
screening started in Finland in 1987 and women aged
50–69 years are invited to mammography biennially [3].
Age and female gender are well-established risk factors
for BC, together with family history with an approximately
twofold increase in risk if one first-degree relative has been
diagnosed with BC [4]. Previous history of BC and certain
benign breast diseases increase the risk [5], as well as high
breast density [6]. There is increasing evidence on the
relationship between female sex hormones and BC [7].
Many full-term pregnancies and young age at first delivery
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decrease BC risk, whereas early age at menarche and old
age at menopause increase it [8–10]. Other well-established
risk factors include use of alcohol and postmenopausal
weight gain which increase the risk, while breast feeding
and physical exercise decrease it [11].
Studies on the association between use of hormonal
contraceptives (HC) and risk of BC have reported con-
flicting results. The prospective Nurses’ Health Study II
concluded with a positive association between oral con-
traceptive use and the risk of BC [12], as did a case–control
study in 2008 [13]. On the other hand, no increase in BC
risk was found in a population-based case–control study
[14]. The role of hormone-releasing intrauterine device
(HR IUD) in the etiology of BC has also been under dis-
cussion, and the results are somewhat contradicting [15–
18]. With respect to use of hormone replacement therapy
(HRT), several studies have indicated that HRT use
increases the risk of BC. The risk is even higher with
longer duration of use and most specifically with the use of
estrogen–progestin combination [19–22].
A retrospective case–control study design is most useful
in assessing lifestyle-related risk factors in rare diseases,
where a prospective setup would be overly expensive and
time-consuming. It is also convenient in obtaining infor-
mation on exposures that cannot be measured by other
means, e.g., with registry linkage. However, the retro-
spective nature of data collection creates potential for
different biases to occur [23]. Validity of survey data and
the role of non-response bias have long been of concern in
epidemiologic research [24–26].
In this study, we aim to estimate the association between
the use of exogenous hormones and BC risk and to assess
the validity and representativeness of the Women’s Health
and Use of Hormones (WHH) survey with respect to var-
ious background and lifestyle factors. The direction and
magnitude of selection and non-response bias will be
studied, and additionally, we evaluate recall bias and
exposure misclassification.
Materials and methods
The nationwide WHH survey was conducted in Finland in
2009. Cases were defined by identifying all women diag-
nosed with BC (in situ or invasive) at 22–60 years of age
between January 01, 2000, and December 31, 2007. Case
identification was done from the Finnish Cancer Registry,
which is population based and nationwide and covers about
99 % of solid tumors [27]. In all, 14,815 women were
identified, of whom 1,550 had died before the survey, leaving
13,265 breast cancer cases in the data (Fig. 1).
Controls were retrieved from the central population
register by a third party under a delivery agreement. First,
four (4) controls per one case were matched with age at
diagnosis (n = 47,511). Erroneous age-matching led to an
imbalance in the number of cases and controls, and to
correct for this, a second matching was conducted by birth
year (n = 16,842). Total number of controls was thus
64,353.
To remove any remaining imbalance in the number of
cases and controls, a further rematching by birth year was
conducted to reach an exact ratio of 1:4. Hence, cases and
controls were randomly excluded, and 10,448 women with
BC and 41,978 controls were left in the data. Of the cases,
951 had had some previous malignancy (data from Cancer
Registry) and were therefore excluded; leaving 9,537
breast cancer cases for the survey, out of whom 6,567
responded (69 %). Of the controls, 23,114 responded the
survey (55 %), and 1,516 reported a previous malignancy
(self-report) and were thus excluded, leaving 21,598 con-
trols in the analytical data set. The study subjects were born
between 1939 and 1984. For better comparability with the
other surveys, WHH responders born before 1945 (640
cases, 1965 controls) were left out from this study to have
equal age cohorts in all the surveys.
The WHH survey was initially developed to address the
association between the use of hormones and risk of BC
[17]. Additionally, the survey mapped out several possible
risk factors for BC, such as family history of BC, age at
menarche, smoking, alcohol use, and body mass index
(BMI). The survey was self-administered and identical for
cases and controls. The aims and objectives of the study
were explained at the cover letter of the survey. The filled
and returned survey was considered as an informed written
consent.
The primary exposures of interest were use of HC, IUD,
and HRT. Original categorization for HC use duration was
‘None,’ ‘\1 month,’ ‘1–6 months,’ ‘[6 months–\2 years,’
‘2–4 years,’ ‘[4–8 years,’ ‘[8–12 years,’ ‘[12–16 years,’
‘[16–20 years,’ ‘[20–25 years,’ and ‘[25 years.’
For analysis, these were pooled to form a binomial
variable, categories ‘\1 month,’ ‘1–6 months,’ and
‘[6 months to\ 2 years’ being categorized into the use of
less than 2 years, the latter ones counting as usage of
2 years or more. Use of IUD was asked as ever- versus
never-use of an intrauterine device, and for ever-users, also
the type of the device was asked, the alternatives being
copper IUD, hormone-releasing IUD, and other IUD. For
further analysis, also a referent category with never-users
of any hormonal contraceptive (HR IUD or other hormonal
contraceptive) was formed. Use of HRT was questioned as
ever- versus never-use without duration specification.
Information on the current use of HRT is used only as a
reference factor in the survey validation (Supplement T1).
It was asked binomially as currently using or not using
HRT without further specifications.
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Conditional logistic regression was used to estimate
odds ratios (ORs) and 95 % confidence interval (CI).
Analyses were stratified by age: those aged 50 years or less
at survey, representing premenopausal women, and those
aged 51 or over, representing postmenopausal respondents.
Univariate results were adjusted for birth year, multivariate
analysis included HC use, use of HR IUD and HRT, age at
menarche, parity, family history of BC, BMI, education,
smoking, and alcohol use.
To assess validity, we compared exposure prevalences
from the WHH with national data from Official Statistics
Finland (OSF) and two other nationwide surveys: the
Fig. 1 Flowchart of the number
of study subjects from
identification to the statistical
analysis in WHH (Women’s
Health and Use of Hormones)
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Health Behavior and Health among the Finnish Adult
Population in 2010 (AVTK, 1,583 female responders) and
the national FINRISK study from 2007 (3,346 female
responders) [28, 29]. Data from OSF were available
regarding education, parity, and marital status. Addition-
ally, the AVTK and FINRISK studies provided information
on alcohol use, smoking, and BMI and on the use of HC,
HR IUD, and HRT.
The study was approved by the ethical committee of
HUS (Helsinki and Uusimaa Health District), decision
number 322/E0/07, and permission for data linkage was
obtained from the National Institute of Health and Welfare
(THL, former STAKES), decision number 2920/605/2008.
Results
The overall response rate in the WHH was 69 % among the
cases and 55 % among the controls (Supplement T1).
Median age of both cases and controls was 57.5 years.
Response percentages varied from 52 to 69 % between the
age groups, being lowest among controls aged 35–44 years
(52 %) and highest in cases aged 35–44 and 55–64 years
(69 %).
A statistically significant increase in BC risk was
observed for postmenopausal women with respect to
exclusive use of HR IUD, when comparing ever-users to
those using or having exclusively used a copper intrauter-
ine device and after adjusting for other risk factors (OR
1.52, 95 % CI 1.14–2.02). When comparing exclusive use
of HR IUD to never-users of any hormonal contraceptive
and when including only cases reporting IUD use before
BC diagnosis, an odds ratio of 1.48 (95 % CI 1.10–1.99)
was observed in postmenopausal women.
Ever-use of HC (other than intrauterine device) was
associated with increased BC risk among premenopausal
respondents (OR 1.32, 95 % CI 1.08–1.61, Table 1), when
compared to never-users. A slight increase was also noted
in postmenopausal women (OR 1.08, 95 % CI 1.01–1.16).
To evaluate the role of more current HC use, we also did
the analysis restricting on cases diagnosed in 2004–2007,
then observing an OR 1.14, 95 % CI 1.02–1.29, in contrast
to that of 0.91, 95 % CI 0.80–1.03 when including only
those diagnosed in the first 2 years (2000–2001) of the
recruitment period (results not shown). Regarding duration
of use, a positive association between long HC use
(C2 years) and BC was observed in both age groups, OR
being 1.37 (95 % CI 1.12–1.68) for premenopausal and
1.11 (95 % CI 1.03–1.20) for postmenopausal women,
when compared to never-users of HC. Unexpectedly, ever-
use of HRT was inversely associated with the risk of BC
among postmenopausal women when compared to never-
users (OR 0.72, 95 % CI 0.67–0.78).
Increased odds ratios were expectedly obtained for those
with high education (OR 1.18, 95 % CI 1.07–1.31 for
postmenopausal women), when compared to those with
B9 years of education (Table 1). Having a family history
of BC was associated with increased risk in both age
groups, OR 1.85 (95 % CI 1.54–2.22) for premenopausal
and OR 1.66 (95 % CI 1.52–1.81) for postmenopausal
women. Risk of BC was elevated also with early age at
menarche (B12 vs. C13 years) in both age groups, OR 1.26
(95 % CI 1.10–1.45) in premenopausal and OR 1.11 (95 %
CI 1.03–1.20) in postmenopausal women. Parity was
inversely associated with BC risk regardless of the
respondent’s age, OR 0.69 (95 % CI 0.56–0.86) in pre-
menopausal women and OR 0.83 (95 % CI 0.74–0.94) for
postmenopausal respondents. Regarding BMI, a statisti-
cally significant inverse association was noted for BMI of
C30 kg/m2 among postmenopausal women, OR 0.83
(95 % CI 0.75–0.91). No relationship was observed
between smoking or alcohol use and BC risk in either of
the age groups when comparing ever-users to never-users.
Validity assessment
Comparisons of the background variables between WHH
and OSF are presented in Table 2. The average difference
between self-reported academic education of the controls
in the WHH and OSF [30] was 8 % points (pp), being
largest among the 25- to 34-year-olds. There were 18 pp
more academically educated responders among WHH
cases and 16 pp more among the controls in this age group,
compared to respective population prevalence. In older age
groups, the difference varied between 6 and 8 pp among
the cases and from 4 to 6 pp among the controls.
Regarding percentages of women ever given birth or
been pregnant, the figures of the controls in WHH differed
on average by 9 pp from the OSF percentages. The largest
difference was again seen in the youngest age group
(25–34 years), where 68 % of the cases and 67 % of the
controls in WHH reported being parous, the corresponding
percentage being 49 % in OSF. Parity figures were more
concordant in other age groups.
According to OSF, the proportion of married women in
the population of the target age cohort in 2009 was 37 %,
which is over twofold less than the figure obtained from the
WHH. In the WHH, however, marriages and common-law
marriages were combined in one category; in the OSF, they
are reported separately. The percentages of divorced
women were by definition more comparable. While the
average percentage of women reporting to be divorced or
separated was 12 % in the WHH, the official figure drawn
from the OSF was 11 %.
Comparisons of the different surveys, WHH, AVTK,
and FINRISK, are presented in Supplement T1. Overall,
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Table 1 Number of subjects and odds ratios for risk factors of breast cancer in Women’s Health and Use of Hormones survey
Variable Category Age at survey
25–50 51–64
Ca Co OR (CI 95 %)
univariate
OR (CI 95 %)
multivariatea
Ca Co OR (CI 95 %)
univariate
OR (CI 95 %)
multivariatea
HC useb Never 120 507 1.0 1.0 1,304 4,450 1.0 1.0
Ever 994 3,208 1.27 (1.05–1.54) 1.32 (1.08–1.61) 3,459 11,290 1.04 (0.98–1.11) 1.08 (1.01–1.16)
NA 3 11 47 165
HC use
duration
\2 year 126 487 1.07 (0.82–1.38) 1.12 (0.85–1.46) 882 3,229 0.95 (0.87–1.04) 0.99 (0.90–1.09)
C2 year 883 2,709 1.33 (1.10–1.62) 1.37 (1.12–1.68) 2,673 8,382 1.08 (1.01–1.16) 1.11 (1.03–1.20)
Never 120 507 1.0 1.0 1,304 4,450 1.0 1.0
NA 108 530 1,255 4,294
Use of
IUD
HR IUD
exclusively
75 261 0.60 (0.44–0.82) 0.59 (0.42–0.82) 73 137 1.50 (1.14–1.96) 1.52 (1.14–2.02)
CU IUD
exclusively
90 173 1.0 1.0 269 793 1.0 1.0
NA 952 3,292 4,468 14,975
HR IUD
exclusively
75 261 0.94 (0.73–1.21) 1.00 (0.77–1.30) 73 137 1.57 (1.24–2.00) 1.63 (1.26–2.11)
CU IUD
exclusively
90 173 1.57 (1.24–1.98) 1.71 (1.34–2.20) 269 793 1.08 (0.94–1.23) 1.14 (0.99–1.32)
Never-use of
IUD
309 998 1.0 1.0 686 2,138 1.0 1.0
NA 643 2,294 3,782 12,837
HR IUD
exclusivelyc
50 261 0.77 (0.54–1.10) 0.79 (0.54–1.17) 56 137 1.36 (1.03–1.79) 1.48 (1.10–1.99)
CU IUD
exclusivelyc
48 173 1.07 (0.75–1.54) 1.21 (0.83–1.78) 175 793 0.78 (0.66–0.93) 0.86 (0.72–1.04)
Never-use of
any HC
50 190 1.0 1.0 370 1,258 1.0 1.0
NA 593 2,104 3,412 11,579
HRT use Never 1,050 3,459 1.0 1.0 2,822 8,398 1.0 1.0
Ever 39 194 0.69 (0.50–0.95) 0.73 (0.51–1.05) 1,833 7,103 0.78 (0.73–0.82) 0.72 (0.67–0.78)
NA 28 73 155 404
Education B9 years 379 1,248 1.0 1.0 2,645 9,236 1.0 1.0
10–12 years 185 581 1.04 (0.87–1.24) 1.01 (0.82–1.24) 409 1,268 1.12 (1.01–1.24) 1.12 (0.99–1.27)
13–16 years 332 1,209 0.91 (0.78–1.05) 0.91 (0.76–1.08) 1,029 3,303 1.08 (1.01–1.16) 1.09 (1.00–1.19)
C17 years 217 659 1.07 (0.90–1.26) 0.98 (0.80–1.20) 701 1,973 1.21 (1.11–1.32) 1.18 (1.07–1.31)
NA 4 29 26 125
Family
history
No 933 3,394 1.0 1.0 3,856 13,903 1.0 1.0
Yes 176 297 1.91 (1.63–2.25) 1.85 (1.54–2.22) 878 1,726 1.67 (1.55–1.80) 1.66 (1.52–1.81)
NA 8 35 76 276
Menarche B12 years 446 1,287 1.22 (1.08–1.37) 1.26 (1.10–1.45) 1,457 4,452 1.11 (1.04–1.18) 1.11 (1.03–1.20)
C13 years 669 2,423 1.0 1.0 3,325 11,382 1.0 1.0
NA 2 16 28 71
Parity No 194 510 1.0 1.0 585 1,533 1.0 1.0
Yes 919 3,205 0.78 (0.67–0.91) 0.69 (0.56–0.86) 4,197 14,284 0.80 (0.73–0.87) 0.83 (0.74–0.94)
NA 4 11 28 88
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the largest differences were observed with regard to HRT
use and regarding parity, education, and HR IUD use in the
youngest age group. Compared to current HRT users in
AVTK and FINRISK, there were significantly more ever-
users of HRT among the controls in the WHH, and a dif-
ference of 5 pp was noted in age group of 45–54 years and
19 pp among the 55- to 64-year-olds. With respect to
parity, young controls (25–34 years) in the WHH reported
significantly more often to be parous, the difference to
FINRISK being 24 pp. Differences in the older age groups
were much smaller, 3–5 pp. Also regarding education, the
difference was highest in the youngest age group, 10 pp.
Other age groups only differed by 0–2 pp. There were
11 pp more ever-users of HR IUD among WHH controls in
the youngest age group compared to FINRISK respondents.
Discussion
We detected positive associations between BC risk and use
of HC and HR IUD. Inverse associations were observed
regarding ever-use of HRT. With respect to use of HR IUD, a
positive association with the risk of BC was observed among
postmenopausal women. This finding is concordant with
those of Lyytinen et al. and Soini et al., who reported an
increased BC risk of postmenopausal users of HR IUD from
register-based studies [16, 37, 42]. This may be due to some
estrogen-related mechanisms promoting tumor growth, or it
may be a result of selection bias, when use of HR IUD is
more often a preferred method of contraception or used as
part of hormone replacement therapy among women with
inherently increased risk of BC, e.g., due to family history.
The reason for the observed association only in post-
menopausal women is also unclear, and most logical
explanation would be latent phase between the exposure and
the onset of BC. In this study, we had the possibility to adjust
the analysis for other major risk factors for BC, including
family history of breast cancer. The results imply that con-
founders do not have an effect on the estimated association
between HR IUD use and risk of BC. In comparison, the
earlier study with partly the same WHH data reported a
rather similar adjusted odds ratio for women B50 years of
age as in our study [17]. Women 50 years or older were not
included in the earlier analyses.
Regarding other HC use, the results are mainly in line
with previous research, with an elevated BC risk especially
among the young women. A large prospective study of
women aged 24–43 years concluded that current HC use
carries an excess risk of BC [12]. Correspondingly, a case–
control study by Rosenberg et al. [13] suggested a positive
association between current HC use and risk of BC, more
specifically in cases diagnosed in the recent years. A
Table 1 continued
Variable Category Age at survey
25–50 51–64
Ca Co OR (CI 95 %)
univariate
OR (CI 95 %)
multivariatea
Ca Co OR (CI 95 %)
univariate
OR (CI 95 %)
multivariatea
BMI (kg/
m2)d
\25 565 1,917 1.0 1.0 1,989 6,376 1.0 1.0
25–29.9 354 1,081 1.10 (0.96–1.25) 1.01 (0.87–1.17) 1,671 5,274 1.01 (0.95–1.08) 0.97 (0.90–1.05)
C30 157 578 0.94 (0.78–1.12) 0.86 (0.70–1.06) 815 3,007 0.88 (0.81–0.96) 0.83 (0.75–0.91)
NA 41 150 335 1,248
Smoking Never 612 2,011 1.0 1.0 2,589 8,437 1.0 1.0
Ever 501 1,698 0.98 (0.87–1.1) 0.95 (0.82–1.09) 2,158 7,287 0.97 (0.92–1.03) 0.99 (0.92–1.06)
NA 4 17 63 181
Alcohol
use
No/Occ. 603 1,927 1.0 1.0 2,714 8,989 1.0 1.0
Regul. 510 1,779 0.93 (0.82–1.04) 0.89 (0.78–1.02) 2,049 6,768 1.01 (0.95–1.07) 0.99 (0.93–1.07)
NA 4 20 47 148
Effect estimates with statistical significance are in bold
a Multivariate model including all listed variables, except for HC use duration, being restricted to ever-users of HC only. In analyses of HC and
HR IUD use, the other contraceptive method was excluded from the model. ORs regarding confounding variables were derived from the model
including HC use only
b Including ever- versus never-use of hormonal contraceptives such as oral contraceptive pills, contraceptive patches, contraceptive implant, and
contraceptive injection
c Only including cases reporting IUD use before breast cancer diagnosis
d Calculated from the height and weight reported in the questionnaire with the formula weight/(height2)
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review by Gierisch and colleagues also concluded with an
increased BC risk of recent use of HC, as did Beaber et al.
[38, 39]. Increased risk estimates for recent HC users
logically relate to younger women, who still are or have
recently been in need for contraception. This intriguing
observation was also done from the WHH, and it deserves
further attention in future studies, considering that there are
also studies reporting null associations between HC use and
BC risk [40, 43].
Our results also implied an inverse association between
HRT use and risk of BC among postmenopausal women,
which is completely opposite to previous research [15, 16].
Stratifying the analysis by family history status did not
change the estimates (results not shown). Controls in the
older age group using or having used HRT are clearly
overrepresented in the WHH, which is probably the reason
for this surprising finding. It seems evident that the esti-
mate for association between HRT use and BC risk is
biased and should be considered with caution.
Regarding traditional BC risk factors, statistically sig-
nificant associations were observed with respect to high
education, family history of BC, early age at menarche, and
nulliparity, suggesting validity of the survey. The reported
multivariate ORs regarding confounding variables were
derived from the model including HC use only, but the
estimates varied very little between the different models.
The observed increased BC risk in women with high
education is in line with previous results, e.g., that of Braaten
et al. [41]. Regarding family history of BC, increased risk
estimates from the WHH study reflect those obtained in large
prospective studies [31]. In WHH, the association was
slightly stronger in premenopausal women, which is con-
cordant with previous findings [4]. Association between early
age at menarche and BC risk was also in line with results from
the referent studies, all reporting slightly elevated risk effects
with earlier menarche age [31, 33–36]. Also age-adjusted
odds ratios for parity in relation to BC risk were of the same
magnitude in WHH as those reported by Reeves et al. [33] and
Kotsopoulos and colleagues [36], all concluding with some
20–25 % lower BC risk estimates for parous women.
An inverse association between obesity (C30 kg/m2)
and risk of BC was observed in postmenopausal women.
Table 2 Percentages of women by age at survey regarding selected risk factors for breast cancer in WHH (Women’s Health and Use of
Hormones) and Official Statistics of Finland (OSF)
Variable 25–34 35–44
OSF WHH
cases,
% (n)
WHH
controls,
% (n)
D cases D controls OSF WHH
cases,
% (n)
WHH
controls,
% (n)
D cases D controls
Education, academic
degree %
15c 33 (11) 31 (39) 118 116 15c 22 (83) 20 (243) 17 15
Marital status,
divorced %
5b 9 (3) 5 (6) 14 0 13b 10 (40) 7 (86) 23 26
Parity, yes % 49d 68 (86)a 67 (86)a 119 118 78d 81 (307)a 84 (1,025)a 13 16
Variable 45–54 55–64
OSF WHH
cases,
% (n)
WHH
controls,
% (n)
D cases D controls OSF WHH
cases,
% (n)
WHH
controls,
% (n)
D cases D controls
Education, academic
degree %
10c 16 (301) 14 (891) 16 14 6c 14 (523) 12 (1,459) 18 16
Marital status,
divorced %
20b 15 (281) 15 (910) 25 25 21b 15 (542) 16 (1,881) 26 25
Parity, yes % 83d 86 (1,588)a 89 (5,542)a 13 16 85d 88 (3,198)a 90 (10 836)a 13 15
Effect estimates with statistical significance are in bold
D Difference between the cases and controls in WHH and OSF in percentage points
a Have been pregnant
b OSF: Population structure [e-publication]. ISSN = 1797-5395. Helsinki: Statistics Finland [referred: 22.10.2014]. Access method: http://
tilastokeskus.fi/til/vaerak/index_en.html
c OSF: Educational structure of population [e-publication]. ISSN = 2242-2919. Helsinki: Statistics Finland [referred: 22.10.2014]. Access
method: http://tilastokeskus.fi/til/vkour/index_en.html
d OSF: Population structure [e-publication]. ISSN = 1797-5395. Annual Review 2009, Women by age, number of children, and the proportion
of those having given birth December 31, 2009. Helsinki: Statistics Finland [referred: 22 October 2014]. Access method: http://www.tilasto
keskus.fi/til/vaerak/2009/01/vaerak_2009_01_2010-09-30_tau_005_en.html
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This is contradictory to previous findings. Kotsopoulos
et al. reported a 50–60 % increase in BC risk in women
with BMI C 30 kg/m2. It is fairly commonly accepted that
a positive association between obesity and BC risk con-
cerns mainly postmenopausal women and the effect might
be the opposite in premenopausal women. In WHH, the
problem is most likely in the retrospective nature of the
survey, where cases might have lost weight after cancer
diagnosis. It is also possible that selection bias has resulted
in well-educated women with healthy lifestyle and lower
BMIs in responding health-related surveys more eagerly.
We did not find association between smoking or alcohol
use and the risk of BC. Also meta-analyses by Hamajima and
colleagues [32] as well as that by Nelson et al. [31] both
reported nonsignificant risk estimates for ever versus never
smokers. Regarding alcohol use, whereas Nelson et al.
reported no association in their meta-analysis, results from the
Million Women Study suggested a significant association
between moderate alcohol consumption and BC risk [33].
Considering validity
In the WHH, response activity of the controls was sub-
stantially lower compared to that of the cases. There was
variation between the age groups; the difference in com-
pliance between cases and controls was largest, on average
15 pp, in the oldest age groups. In general, the response
rates were highest among the older responders in all con-
sidered surveys.
OSF was considered to offer nearly complete data on the
given variables, and hence, it enabled us to reliably assess
the level of non-response bias in the WHH survey [44].
AVTK and FINRISK studies were considered suitable ref-
erents due to their established nature as routine, official
nationwide health surveys conforming to the guidelines of
the European Health Risk Monitoring project [45].
Exposures that are evidently related to an increased BC
risk, such as high education and nulliparity, were seen in
WHH as large percentages of academically educated,
nulliparous cancer cases, compared to that of the controls.
Comparison of the WHH and OSF also showed great dis-
parities in the percentages of academically educated, par-
ous women. This phenomenon was especially seen among
young study participants, the differences evening out in the
older age groups. This returns to the well-known phe-
nomenon, where survey responders often are highly edu-
cated and living in a relationship [46]. This makes factors
confounded by the socioeconomic status more difficult to
assess and may reduce the representativeness of the results.
It also affects, e.g., smoking and alcohol use and estima-
tions of their role in the etiology of BC. To account for the
differences in the distribution of the educational level in
the WHH responders versus non-responders, we stratified
the analysis of HR IUD and HC use by education. This did
not change the results regarding the association between
HR IUD and BC, the odds ratio still being stronger and
statistically significant in postmenopausal women regard-
less of education. With respect to HC use, the observed
effect in premenopausal women was diluted and statisti-
cally significant association was no longer seen in either
age group (results not shown).
As with all retrospective case–control studies, recall bias
was of concern in this study. Time between cancer diag-
nosis and the survey varied from 1 to 9.5 years, the median
being 5.5 years. Generally, the longer the time from the
diagnosis, the fewer respondents. Likewise, the longer the
time elapsed between diagnosis and the survey, the more
may be missed of aggressive types of cancer due to death.
This was observed in the WHH study, where some 70 % of
the cancer cases who died before the survey were meta-
static at diagnosis, whereas less than 40 % of the cancers
included in the study were metastatic at diagnosis. There
were no differences in spreading of the cancer among the
responders and non-responders.
Differences between the surveys indicate that non-re-
sponse bias is more likely in a topic-specific survey such as
the WHH and especially when the study participants are
aware of the main study question. This observation is con-
cordant with earlier estimations reporting that people are
40 % more likely to respond to a survey with a topic of
special interest to them [47]. It is possible that knowing the
focus of the WHH survey (hormone use) may have drawn
more hormone-users to answer the survey. Also, use of
hormonal contraceptives may not have been considered as
‘use of hormones’ in the same sense as HRT use, resulting in
more representative user prevalences regarding contracep-
tives. It must also be noticed that in the WHH, the percent-
ages of HRT users include also women using HRT due to
hysterectomy and/or oophorectomy. Nevertheless, discrep-
ancies in HRT user prevalence between the surveys are
considerable. In contrast, reporting of some lifestyle factors
was surprisingly consistent between the surveys, concerning
for instance smoking. Overall, the WHH survey seemed to
serve well with respect to use of hormonal contraceptives as
well as regarding most of the background variables and
potential confounders included in the questionnaire. The
above-mentioned biases must, however, be taken into
account when interpreting the results from surveys.
In conclusion, the observed association between HR
IUD use and risk of BC in postmenopausal women
deserves further attention, since the estimate is not likely to
be severely biased. Even if the potential increase in risk of
BC produced by HR IUD use would be small, taken the
high prevalence of their use into account, the impact in
public health could be considerable. Previous studies on the
topic are scarce and an extensive prospective cohort study
256 Cancer Causes Control (2016) 27:249–258
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is encouraged. Correspondingly, the increased BC risk
estimates observed especially in premenopausal women
regarding other HC use and elevated risk estimates for
women with recent diagnosis are also of interest. The
surprising HRT finding is very likely to be biased due to
lack of representativeness of the HRT user population and
should be ignored.
We emphasize the benefits of the use of reference
population information on risk factors whenever available
in order to assess potential bias, especially in case–control
studies with survey information. This increases validity and
improves interpretation of the results as well as guide in
leaving out such study questions that are severely biased in
the future studies.
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